1Zaghloul MS. Adjuvant and neoadjuvant radiotherapy for bladder cancer: revisited[ J]. Future Onco1,2010,6 (7) : 1177 - 1191.
2Van Doren SR, Wei S, Gao G, et al. Inactivation of N - TIMP - 1 by N- terminal acetylation when expressed in bacteria [ J ]. Biopolymers,2008,89 ( 11 ) :960 - 968.
4Liotta LA, Steeg PS, Stetler-stevenson WG. Cancer metastasis and angiogenesis:an imbalance of positive and negative regulation[J]. Cell, 1991,64 : 327-336.
5AI-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer[J]. Cancer,2003,97(suppl 8) :2064-2075.
6Bellon C, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis[J]. Crit Rev Oncol Hematol, 2004, 49(3) :203-220.
7Jodele S, Chanreain CF, Blavier L, et al. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent[J]. Cancer Res, 2005,65(8) :3200-3208.
8Papathoma AS, Petrarki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinase 2 and 9 in bladder cancer[J]. Anticancer Res, 2000,20(8):2009.
9Kanoyama H, Yokotal K, kurokawa Y, et al. Prognostic values of matrixmetalloproteinase-2 andtissue inhibitor of matrix metalloproteinase-2 expression in bladder cancer[J]. Cancer, 1998,82(7):1359.
10Shiina H, Igawa M, Yagi H, et al. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder[J]. Ear Urol,1996,30(1) :80-88.
3Ramón de Fata F,Ferruelo A,Andrés G,et al.The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinasas as serum markers of bladder cancer[J].Actas Urol Esp,2013,37(8):480-488.
4Wieczorek E,Reszka E,Jablonowski Z,et al.Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs),and bladder cancer susceptibility[J].BJU Int,2013,112(8):1207-1214.
